All lobbying filings

DAIICHI SANKYO, INC.

Lobbying for DAIICHI SANKYO INC

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $130,000.00 expenses · posted Apr 20, 2026

Official filing document

Bills named in this filing 2

HR 946
ORPHAN Cures Act
HR 2319
Women and Lung Cancer Research and Preventive Services Act of 2025

Lobbying activity 4

Health Issues

Discussions regarding H.R.946, the ORPHAN Cures Act Discussions related to H.R.2319, the Women and Lung Cancer Research and Preventative Services Act Discussions related to the Protecting Patient Access to Cancer and Complex Therapies Act reintroduction Issues related to most-favored-nation and other foreign reference drug pricing policy Issues related to the Food and Drug Administration

Taxation/Internal Revenue Code

Discussions regarding tax reform and tariffs

Medicare/Medicaid

Issues related to the Medicare Drug Price Negotiation Program

Issues related to intellectual property rights

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.